What bloodwork should I get before and during peptide use?

The short answer

Bloodwork turns peptide use from guesswork into something you can actually monitor. A baseline panel before you start, the right peptide-specific markers tracked during use, and a recheck afterward let you catch problems early and see whether the compound is doing what's claimed — which, given the thin evidence and lack of oversight, is among the most responsible things a user can do.

Evidence tier: This is Tier 2–3. The value of baseline and monitoring bloodwork is well-established clinical practice; which specific markers matter for which peptide is mechanism-based and, for some, thinly studied.

The essentials:

• Get a baseline before starting — you can't detect a change without it.
• Track peptide-specific markers — e.g. IGF-1 for GH secretagogues, glucose for MK-677.
• A clinician should interpret results — numbers need context.
• Recheck after to confirm nothing drifted and the effect held.

This is part of our beginner cluster; see the peptide beginner's guide and, for context on tolerance and monitoring, the peptide cycling cornerstone.

Why baseline bloodwork comes first

Evidence tier: 2 — fundamental monitoring principle.

The single most useful lab habit is getting a baseline before you start anything, because a change is only detectable against a reference. If you measure a marker for the first time during a peptide cycle and it's slightly off, you can't tell whether the peptide caused it or it was always that way. A pre-cycle baseline turns later results into a before-and-after comparison, which is what makes monitoring meaningful rather than ambiguous.

A sensible baseline for most people includes the general-health panels a clinician would run anyway: a complete blood count, a comprehensive metabolic panel (including glucose, kidney, and liver markers), a lipid panel, and — depending on the compound and goals — markers like HbA1c, fasting insulin, or hormones. These establish where you stand on the things peptides could plausibly affect, and they sometimes surface an unrelated issue worth addressing before adding any compound. Getting this baseline through a clinician, who can both order and interpret it, is the ideal; it also opens the door to the medical oversight that gray-market peptide use otherwise lacks. Our beginner's guide frames where this fits in getting started.

Which markers matter for which peptide

Evidence tier: 2–3 — mechanism-based monitoring.

The peptide-specific markers follow from the mechanism, and matching them correctly is the skill. For GH secretagogues (CJC-1295/ipamorelin, MK-677, sermorelin), the key downstream marker is IGF-1, which reflects GH-axis activity — a baseline and on-cycle IGF-1 shows whether the pathway is responding and whether it's drifting out of range (Sigalos 2018). MK-677 specifically warrants attention to fasting glucose, HbA1c, and insulin sensitivity, since it can affect blood sugar. For GLP-1s, monitoring tends to focus on metabolic markers — glucose, HbA1c, lipids — and clinical response, with attention to any signals a prescriber flags. For peptides with little systemic-marker footprint (many recovery peptides), there's less specific bloodwork to track, and monitoring leans more on the functional outcome.

The general rule is to ask, for any compound, "what would this plausibly change, and can I measure it?" — then track those markers specifically rather than running random panels. This targets the monitoring where it's informative. It also calibrates interpretation: a rising-then-plateauing marker, a value drifting out of range, or a metabolic shift each mean something specific in context. Because that interpretation genuinely requires clinical knowledge, having a clinician read the results is far better than self-interpreting numbers off a lab report. Our GH secretagogue cycling article covers IGF-1 monitoring in depth, and the GLP-1 complete guide the metabolic side.

What bloodwork can and can't tell you

Evidence tier: 2–3 — interpretation limits.

It's worth being clear about the limits, because bloodwork is powerful but not omniscient. It can confirm that a pathway is responding (IGF-1 rising on a GH secretagogue), flag a developing problem (glucose creeping up on MK-677, a liver or kidney marker drifting), and provide an objective check against subjective impressions that are prone to placebo. Those are real, valuable functions that make monitoring worthwhile.

What it can't do is capture everything. Many peptide effects — and side effects — don't show up cleanly on a standard panel, the right specialized test may not exist or be accessible, and a normal result doesn't guarantee safety any more than an abnormal one proves harm. Bloodwork is one input, not a complete safety verdict, and it should be combined with how you actually feel and function, and with a clinician's judgment. Over-relying on labs ("my bloodwork is fine, so anything goes") is as much a mistake as ignoring them. The honest stance is that monitoring meaningfully improves your information without making gray-market peptide use fully safe — it reduces blind spots rather than eliminating them. This pairs with the functional tracking covered in our beginner's guide.

How often should I test, and with whom?

Evidence tier: 2–3 — practical monitoring cadence.

A reasonable rhythm for many users is a baseline before starting, a recheck partway through a longer cycle (to catch drift while you can still act on it), and a recheck after finishing (to confirm markers returned to or stayed in range and to see whether any change tracked the compound). The exact cadence depends on the peptide, the dose, and the markers — a compound with real metabolic effects like MK-677 warrants closer watching than a recovery peptide with little systemic footprint. The principle is to test often enough to catch a developing problem before it becomes significant, not so often that you're chasing noise.

The "with whom" matters as much as the "how often." Involving a clinician — to order appropriate tests, interpret them in context, and advise on what a given result means for continuing or stopping — is what turns raw numbers into informed decisions, and it's the single best way to add real medical oversight to otherwise-unsupervised peptide use. Many people can access labs directly, but interpretation is where clinical knowledge is irreplaceable; a value that looks fine to a layperson may concern a clinician, and vice versa. Where a prescribing or monitoring clinician is involved, that's the safest configuration; where one isn't, getting at least interpretation help is a strong second best. Our peptide safety and sourcing guide covers the broader safety framework this fits into.

Getting labs done affordably and consistently

Evidence tier: 3–4 — practical access.

A common barrier is that people assume bloodwork requires a doctor's visit and is expensive, so they skip it — which is the worst outcome, since some monitoring is far better than none. In practice there are several routes. Working through a primary care clinician is ideal because it bundles ordering, interpretation, and oversight, and routine panels are often covered by insurance, especially if there's a general-health rationale. Where that's not accessible, direct-to-consumer lab services let you order common panels yourself at modest cash prices, which makes a baseline and follow-up genuinely affordable for most people — though you then need to arrange interpretation separately, since a results PDF without context is only half the value.

Two practices make whatever route you choose more useful. Consistency matters: using the same lab and testing under similar conditions (e.g., fasting in the morning for glucose and lipids) reduces the noise that can make a real change hard to see or a meaningless fluctuation look alarming. And keeping your own record of results over time turns isolated numbers into a trend you and a clinician can actually read — the same tracking discipline that applies to the peptide's functional effects. The goal isn't an exhaustive, expensive workup; it's a sensible baseline plus the few mechanism-relevant markers, done consistently and interpreted with help. That's affordable and achievable for most people, and it's a large step up from flying blind. Our beginner's guide covers how this fits the broader getting-started process.

Limitations

This is an educational guide, not medical advice or a monitoring protocol.

• Baseline bloodwork before starting is what makes later results interpretable.
• Markers should match the compound's mechanism — IGF-1 for GH secretagogues, glucose for MK-677.
• A clinician should interpret results — numbers need clinical context.
• Normal labs don't guarantee safety — bloodwork is one input, not a full verdict.
• Many peptide effects don't show on standard panels — combine with functional tracking.
• Gray-market sourcing carries real risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Bloodwork is what turns peptide use from guesswork into monitored use. Get a baseline before starting — you can't detect a change without it — then track the markers that match the compound's mechanism: IGF-1 for GH secretagogues, glucose and HbA1c for MK-677, metabolic markers for GLP-1s, with less specific bloodwork for recovery peptides that have little systemic footprint. Recheck partway through a longer cycle and after finishing. And have a clinician interpret the results, because numbers need context and a clinician is also the best way to add real oversight to otherwise-unsupervised use.

The right mental model is that bloodwork is a powerful but partial instrument: it catches developing problems early, confirms whether a pathway is responding, and provides an objective check against placebo — but it doesn't capture every effect, and normal results don't certify safety. So it belongs alongside honest functional tracking and clinical judgment, not as a standalone green light. For anyone using compounds that are unapproved and unmonitored by default, baseline-and-follow-up bloodwork interpreted by a clinician is among the highest-value safety habits available — it won't make gray-market peptides fully safe, but it meaningfully reduces the blind spots, which is exactly the responsible direction to move in.

Related on this site

• Peptides for beginners (cornerstone)
• Your first peptide cycle: a walkthrough
• Common beginner peptide mistakes
• GH secretagogue cycling and desensitization
• GLP-1 complete guide (2026)
• Peptide safety and sourcing guide (2026)
• Our evidence-tier framework
• Finnrick vendor testing

References

• Sigalos JT, Pastuszak AW. 2018. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 6(1):45-53. PMID 28330835 — IGF-1 as the GH-axis monitoring marker.
• Nass R, Pezzoli SS, Oliveri MC, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 149(9):601-611. PMID 19011247 — MK-677 effects on IGF-1 and glucose metabolism.
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — metabolic-marker context for GLP-1 monitoring.